Democrats' election victory tees up new scrutiny of Trump's Big Pharma deals
A shifted political landscape could change leverage over most-favored-nation pricing and pharma policy deals.
Read at Bloomberg Law News →Full coverage · 6 outlets
- Bloomberg Law News · lead
- BioSpaceWith MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
- Pharma VoiceThe Democrats are coming. Here’s how they want to change pharma and healthcare.
- ing thinkDemocratic victories to constrain President Trump and increase tech scrutiny
- Mining.comDemocrats’ win puts US mining agenda under scrutiny
- TradingView‘Lawyer up’: Democrats target Trump, Big Tech after midterm sweep